Update on capecitabine alone and in combination regimens in colorectal cancer patients.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cancer Treatment Reviews

• Publication date

  2010-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0305-7372(10)70020-7PMID 21129610
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Irinotecan/capecitabine (XELIRI) plus bevacizumab versus irinotecan/fluorouracil/leucovorin (FOLFIRI) plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: A randomized phase III trial of the Hellenic Cooperative Oncology Group (HeCOG).

  2010cited by this paper
• Cetuximab and chemoradiation for rectal cancer–is the water getting muddy?

  2010cited by this paper
• Evolution of capecitabine dosing in colorectal cancer.

  2010cited by this paper
• Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.

  2010cited by this paper
• Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.

  2010cited by this paper
• Predictive value of MSI, 18qLOH, TS promoter, and MTHFR C677T variants on efficacy/toxicity of capecitabine adjuvant monotherapy: A mid-term report of a prospective observational study on 136 stage II/III colon cancer patients.

  2010cited by this paper
• Neoadjuvant bevacizumab, capecitabine, and radiotherapy in locally advanced rectal cancer: Interim results of a phase II CRAB trial.

  2010cited by this paper
• A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer.

  2010cited by this paper
• Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): Impact of age on disease-free survival (DFS).

  2010cited by this paper
• Routine omission of sentinel lymph node biopsy for merkel cell carcinoma <= 1 cm is not justified.

  2010cited by this paper
• Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer--is it equivalent to 5-FU infusion plus leucovorin and radiotherapy?

  2010cited by this paper
• Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor

  2009cited by this paper
• Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.

  2009cited by this paper
• Molecular analysis of Mycobacterium isolates from extrapulmonary specimens obtained from patients in Mexico

  2009cited by this paper
• Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo-)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Safety results of a randomized, phase III trial.

  2009cited by this paper
• 5LBA First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study)

  2009cited by this paper
• Bi-weekly administration of capecitabine + oxaliplatin (Xelox-2) in first-line treatment of advanced colorectal cancer (ACRC): A phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).

  2009cited by this paper
• The role of capecitabine in the management of tumors of the digestive system.

  2009cited by this paper
• Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.

  2008cited by this paper
• Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

  2008cited by this paper
• Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.

  2008cited by this paper
• Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.

  2008cited by this paper
• Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

  2008cited by this paper
• Bi-weekly administration of capecitabine + oxaliplatin (XELOX-2) in first line treatment of advanced colorectal cancer (ACRC): Preliminary results

  2008cited by this paper
• Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

  2008cited by this paper
• Folfiri versus xeliri in untreated advanced colorectal cancer: A phase II randomised trial of the Gruppo Oncologico dell’ Italia Meridionale (prot. GOIM 2405)

  2008cited by this paper
• The use of capecitabine in the combined-modality therapy for rectal cancer.

  2008cited by this paper
• Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer.

  2008cited by this paper
• Potential regional differences for the tolerability profiles of fluoropyrimidines.

  2008cited by this paper
• Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.

  2007cited by this paper
• Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.

  2007cited by this paper
• Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.

  2007cited by this paper
• Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.

  2007cited by this paper
• Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.

  2007influential reference
• Capecitabine Plus 3-Weekly Irinotecan (XELIRI Regimen) as First-Line Chemotherapy for Metastatic Colorectal Cancer: Phase II Trial Results

  2007cited by this paper
• Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.

  2006cited by this paper
• Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.

  2006cited by this paper
• Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study

  2006cited by this paper
• Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study.

  2006cited by this paper
• The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer

  2006cited by this paper
• A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer.

  2006cited by this paper
• Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer.

  2006cited by this paper
• The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?

  2006cited by this paper
• Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer.

  2006cited by this paper
• Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.

  2005cited by this paper
• A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.

  2005influential reference
• A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.

  2005cited by this paper
• Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study.

  2005influential reference
• Capecitabine as adjuvant treatment for stage III colon cancer.

  2005cited by this paper
• Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation.

  2005cited by this paper
• Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study.

  2005cited by this paper
• Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.

  2005cited by this paper
• A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer

  2004cited by this paper
• XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.

  2004cited by this paper
• Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinoma

  2004cited by this paper
• Preoperative versus postoperative chemoradiotherapy for rectal cancer.

  2004cited by this paper
• Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine

  2004cited by this paper
• Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

  2004cited by this paper
• Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.

  2004cited by this paper
• Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer.

  2003cited by this paper
• 295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial

  2003cited by this paper
• Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer.

  2003cited by this paper
• Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule.

  2002cited by this paper
• Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer.

  2002cited by this paper
• Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.

  2002cited by this paper
• Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.

  2002cited by this paper
• Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials.

  2002cited by this paper
• Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

  2001cited by this paper
• Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

  2001cited by this paper
• Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.

  2000cited by this paper
• Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

  1998cited by this paper
• Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.

  1998cited by this paper
• Patient preferences for oral versus intravenous palliative chemotherapy.

  1997cited by this paper
• Enhancement of the antitumor effect of gamma-ray irradiation in combination with camptothecin against human colorectal adenocarcinoma.

  1996cited by this paper

• Triacanthine enhances the sensitivity of colorectal cancer cells to 5-fluorouracil by regulating RRM2.

  2023cites this paper
• Measurement of 5- fluorouracil, capecitabine and its metabolite concentrations in blood using volumetric absorptive microsampling technology and LC-MS/MS.

  2021cites this paper
• CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy

  2019cites this paper
• Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.

  2018cites this paper
• Novel fluoropyrimidine-based chemotherapy for advanced well-differentiated neuroendocrine tumors: a clinical update

  2018cites this paper
• Oral versus intravenous fluoropyrimidines for colorectal cancer.

  2017cites this paper
• Comparative in-vivo Evaluation of Anti-Cancer Drugs Loaded Nanospheres

  2017cites this paper
• Effets secondaires intestinaux des médicaments

  2016cites this paper
• A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer

  2016cites this paper
• 5-Fluorouracil derivatives: a patent review (2012 – 2014)

  2015cites this paper
• Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells.

  2015cites this paper
• Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis.

  2014cites this paper
• In vitro synergistic interaction between amide piplartine and antimicrobial peptide dermaseptin against Schistosoma mansoni schistosomula and adult worms.

  2013cites this paper
• Effets secondaires intestinaux des médicaments

  2013cites this paper
• [Cost analysis of XELOX and FOLFOX-4 chemotherapy regimens for colorectal carcinoma].

  2012cites this paper
• Role of CIP2A in carcinogenesis

  2012cites this paper
• Can You Determine the Cause of This Patient’s Skin Changes?

  2012influential citation
• 5-Fluorouracil derivatives: a patent review

  2012cites this paper
• In Vitro Synergistic Interaction Between Amide Piplartine and Antimicrobial Peptide Dermaseptin Against Schistosoma mansoni Schistosomula and Adult Worms

  2012cites this paper
• ROLE OF CIP 2 A IN CARCINOGENESIS

  2012cites this paper
• Liver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches.

  2011cites this paper
• Interactions of mefloquine with praziquantel in the Schistosoma mansoni mouse model and in vitro.

  2011cites this paper